The MHRA has opened a consultation to make oxybutynin hydrochloride tablets, used for the treatment of overactive bladder, available without prescription


The Medicines and Healthcare products Regulatory Agency (MHRA) has called on pharmacists, other healthcare professionals, and the public for their views on reclassifying Aquiette 2.5 mg tablets, which are currently prescription-only.

Aquiette 2.5mg tablets contain oxybutynin hydrochloride and are used to treat women with milder symptoms of overactive bladder that are not controlled by bladder training alone. Symptoms include having to urinate at least eight times in the day and more than once during the night, sometimes leading to accidental leaks.

If positive responses are received and the decision is made to reclassify this treatment, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this medicine safely.

This would be the first time a medicine for the treatment of overactive bladder would be available without prescription.

Dr Laura Squire, Chief Healthcare Quality and Access Officer at the MHRA, said: ‘We encourage women and healthcare professionals who have experience of using this vital treatment to engage with the consultation and make your views heard. Every response we receive will help us gain a better picture of whether people think this reclassification would be beneficial.

‘Living with an overactive bladder can be extremely difficult, which is why it’s so important that we hear from as many people and women’s groups as possible.

‘We are thoroughly committed to improving access to medicines where it is safe to do so.’

View our Guidelines summary on urinary incontinence here


Lead image: 9nong/

Image 1: 9nong/